Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

3.150 +0.010 (+0.32%)
Official Closing Price Updated: 7:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 Next >
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jefferies London Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Top 4 Health Care Stocks That May Plunge This Quarter
 
Via Benzinga
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
From Nuvation Bio Inc.
Via Business Wire
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
From Nuvation Bio Inc.
Via Business Wire
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Nuvation Bio to Present at the Cantor Global Healthcare Conference
From Nuvation Bio
Via Business Wire
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
From Nuvation Bio Inc.
Via Business Wire
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
 
Via Benzinga
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024
NUVB stock results show that Nuvation Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
From Nuvation Bio Inc.
Via Business Wire
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
Via Benzinga
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. 
Via Benzinga
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because... 
Via Talk Markets
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
From Nuvation Bio Inc.
Via Business Wire
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.